Skip to content
Peptide research

Pentapeptide-18

Also known as Leuphasyl
Category
Skin & Cosmetic
Administration routes
Topical
Regulatory status
Cosmetic ingredient

A synthetic pentapeptide in wrinkle serums that mimics enkephalins to relax facial muscles, marketed as a Botox alternative. Evidence is limited to small, open-label, manufacturer-funded trials with modest results, not blinded studies; other benefits are speculative, from lab or computational work. No serious adverse effects are reported, but long-term safety data are scarce; it remains unapproved, sold as a cosmetic ingredient, not a research peptide.

This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer

Compiled from published research indexed through March 2026.

Overview

Pentapeptide-18, sold commercially as Leuphasyl, is a five-amino-acid peptide designed to reduce expression wrinkles (like forehead lines and crow's feet) by gently relaxing the facial muscles that cause them. It is a synthetic version of leu-enkephalin, a natural pain-relieving molecule your body produces, repurposed here for its ability to calm nerve signaling at the skin surface. Unlike Botox, which must be injected and fully paralyzes muscles, Pentapeptide-18 is applied topically and softens — rather than freezes — facial movement. It was developed by Lipotec (now part of Lubrizol) and introduced in 2005.

How it works in the body

Mimics the action of enkephalins (natural pain-relieving peptides) at the nerve-muscle junction in skin. It binds to opioid-like receptors on nerve endings, reducing the release of acetylcholine at the neuromuscular junction. This relaxes facial muscle contractions that cause expression lines.

Research overview

Pentapeptide-18 works by binding to enkephalin (opioid) receptors on nerve cells near the skin surface, triggering a cascade that reduces the release of acetylcholine — the chemical messenger that tells muscles to contract. The result is a gentle relaxation of the repetitive muscle movements that create expression lines. In the manufacturer's study, a cream with 0.05% active peptide applied twice daily for 28 days reduced wrinkle depth by about 12%. With Argireline added (it blocks muscle contraction through a different mechanism), wrinkle reduction was roughly 25%, with some subjects reaching nearly 47%. An independent clinical study (Dragomirescu et al. 2014, 20 volunteers) found that a 2% concentration is the minimum needed for significant results, achieving 35% wrinkle reduction on the forehead and 28% around the eyes after two months. Limitations include small study sizes (14-20 subjects), no large placebo-controlled trials, and no long-term safety data beyond two months.

Who researches Pentapeptide-18?

Commonly researched by

  • People researching skin health and rejuvenation

    Studied for collagen synthesis, skin repair, or anti-aging skin effects.

  • People researching longevity and anti-aging interventions

    Studied for effects on aging pathways, cellular health, or lifespan extension.

Important considerations for

  • Those who are pregnant or breastfeeding

    Absolute

    No human reproductive safety data exists for this peptide. Effects on fetal development are unknown.

  • Anyone under 18

    Absolute

    No pediatric safety data. Not recommended for use in minors.

  • Those with Known hypersensitivity

    Absolute

    Discontinue immediately if allergic reaction occurs (rash, swelling, difficulty breathing).

Safety & interactions

General cautions

  • Pregnancy or breastfeeding

    Absolute

    No human reproductive safety data exists for this peptide. Effects on fetal development are unknown.

  • Children under 18

    Absolute

    No pediatric safety data. Not recommended for use in minors.

  • Known hypersensitivity

    Absolute

    Discontinue immediately if allergic reaction occurs (rash, swelling, difficulty breathing).

How to read the ratings

Benefits
= confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)
Risks
= level of concern: High · Moderate · Low · Theoretical
Interactions
= direction with this peptide: Protective / Synergistic · Caution · Neutral

Risk summary(4)

Rated by level of concern

  • No known serious adverse effects

    Low

    PMID 42116636 (Chem Biodivers 2026; HaCaT non-cytotoxic, in silico ADMET); PMID 41722287 (ADMET modeling)

  • Potential skin sensitivity in hypersensitive individuals

    Low

    General topical-cosmetic dermatology; no identified PubMed-indexed dermatitis or sensitization reports for pentapeptide-18

  • Limited long-term safety data

    Moderate

    No identified ClinicalTrials.gov registrations for pentapeptide-18; PubMed record limited to in vitro, in silico, and formulation studies (PMIDs 31937863, 39337562, 39459512, 41722287, 42116636)

  • Theoretical opioid receptor activation

    Theoretical

    PMID 41722287 (enkephalin-analog mechanism, ADMET modeling); no human PK data identified

Interaction summary(7)

Rated by direction with this peptide

  • Botulinum toxin type A (onabotulinumtoxinA, abobotulinumtoxinA)

    NeutralTheoretical

    Marketed as complementary because both are framed as reducing acetylcholine-mediated contraction (pre-synaptic modulation vs SNARE cleavage), but no study has tested topical pentapeptide-18 alongside injected neuromodulator and there is no evidence the peptide reaches the neuromuscular junction. Treated as neutral rather than synergistic because no additive effect has been demonstrated; no safety concern is documented either.

    Mechanistic inference from PMID 41722287; no identified combination study in PubMed or ClinicalTrials.gov

  • Acetyl Hexapeptide-8 (Argireline)

    NeutralTheoretical

    Commonly co-formulated on the rationale of complementary points of action on acetylcholine release, but the synergy is a supplier claim with no peer-reviewed combination data in humans or in vitro. Co-use is not known to be problematic; the claimed benefit is simply unverified.

    No identified PubMed-indexed combination study for pentapeptide-18 and acetyl hexapeptide-8

  • Retinol and topical retinoids

    NeutralLow

    Co-encapsulation of retinol with pentapeptide-18 in solid lipid nanoparticles and lipid nanocarriers has been characterized and is physicochemically compatible. Compatibility is not the same as efficacy synergy, which has not been tested; retinoid-driven irritation remains the dose-limiting factor in such combinations rather than any peptide effect.

    PMID 39337562 (Int J Mol Sci 2024); PMID 39459512 (Life 2024)

  • Alpha/beta hydroxy acids and other barrier-disrupting exfoliants

    CautionLow

    Acid pre-treatment increases stratum corneum permeability and can raise peptide penetration and local irritation; low pH can also destabilize peptide formulations, so layering is best separated in time. General formulation pharmacology, not a pentapeptide-18-specific finding.

    General topical-formulation pharmacology; no pentapeptide-18-specific study identified

  • Opioid antagonists (naloxone, naltrexone; including low-dose naltrexone)

    NeutralTheoretical

    An opioid antagonist would in principle block an enkephalin-analog's receptor-mediated action, but with no demonstrated systemic absorption of topical pentapeptide-18 there is no evidence of a clinically meaningful interaction in either direction.

    Mechanistic inference from enkephalin-analog structure (PMID 41722287); no interaction data published

  • Systemic opioid therapy or opioid-use-disorder treatment (buprenorphine, methadone)

    NeutralTheoretical

    Topical cosmetic use is not expected to add systemic opioid activity or to interfere with treatment or urine drug screening, given no evidence of intact-peptide transdermal absorption; the concern is structural, not pharmacokinetic.

    No human pharmacokinetic study of pentapeptide-18 identified; no clinical interaction reports

  • Tyrosinase-inhibiting brighteners (hydroquinone, kojic acid, arbutin)

    NeutralTheoretical

    No interaction is expected for standard pentapeptide-18, which showed no anti-melanogenic effect. Additive depigmenting action is a possibility only for the D-tyrosine-conjugated analog studied in cell and 3D-skin models - a different molecule from the ingredient sold as pentapeptide-18.

    PMID 31937863 / PMC6959337 (Sci Rep 2020;10:262)

Known risks(4)

  • No known serious adverse effects

    Minimal

    All available studies (manufacturer testing and independent clinical studies) report excellent safety and tolerance. No cytotoxicity, genotoxicity, skin irritation, allergic reactions, or systemic adverse effects have been observed in any published study. The peptide is applied topically at very low active concentrations (0.03-0.1%) and minimal systemic absorption is expected.

  • Potential skin sensitivity in hypersensitive individuals

    Low

    While no irritation or sensitization has been reported in clinical studies, individuals with extremely sensitive skin or known peptide allergies may theoretically experience mild irritation. A patch test is recommended before first use as a precautionary measure.

  • Limited long-term safety data

    The longest published clinical study spans 2 months (Dragomirescu et al. 2014). No studies have assessed safety of continuous daily application over years, which is how many consumers use anti-aging products. Long-term effects are unknown but considered low risk given the ingredient's topical application, low concentration, and minimal systemic absorption.

  • Theoretical opioid receptor activation

    Negligible (topical cosmetic use)

    As an enkephalin analog, Pentapeptide-18 binds to opioid receptors. However, at the concentrations used in cosmetic formulations (0.03-0.1% active) and via topical application with minimal systemic absorption, there is no risk of opioid-like systemic effects (analgesia, sedation, dependence). The skin's endogenous opioid system plays a physiological role in cell differentiation and wound repair, and topical opioid peptides do not cross the blood-brain barrier at cosmetic doses.

Drug interactions(4)

  • No known pharmaceutical drug interactions (topical cosmetic use)

    Pentapeptide-18 is a topical cosmetic ingredient applied at very low concentrations (0.03-0.1% active) with minimal systemic absorption. No pharmaceutical drug interactions have been reported or are expected. It is not absorbed into the bloodstream in meaningful quantities and does not undergo hepatic metabolism or renal excretion at detectable levels.

  • Other topical neuromuscular peptides (Argireline/Acetyl Hexapeptide-8, Syn-Ake/Dipeptide Diaminobutyroyl Benzylamide Diacetate)

    Synergistic (beneficial) interaction. The combination of Pentapeptide-18 with Argireline produces additive-to-synergistic wrinkle reduction (24.62% vs 11.64% or 16.26% alone) due to complementary mechanisms at different stages of the neuromuscular signaling cascade. Similarly, combination with Syn-Ake (which mimics waglerin-1 snake venom peptide) may provide additional complementary neuromuscular modulation. These are intentional cosmetic combinations, not adverse interactions.

  • Topical retinoids (tretinoin, retinol, adapalene)

    No adverse interaction. Pawlowska et al. (2024) specifically demonstrated that co-formulating Pentapeptide-18 with retinol in nanoparticle delivery systems is safe and effective, and may actually reduce the irritation typically associated with retinoid therapy. The two ingredients have complementary mechanisms (neuromuscular modulation + collagen stimulation/cell turnover).

  • Botulinum toxin injections (Botox, Dysport, Xeomin)

    Theoretical additive neuromuscular effect if topical Pentapeptide-18 is used over areas treated with botulinum toxin injections. However, given the modest potency of topical Pentapeptide-18 compared to injected botulinum toxin, clinically significant interaction is unlikely. Many cosmetic protocols use topical neuropeptide serums between Botox sessions to maintain results.

Research & benefits

Evidence base

Evidence Level
Moderate
Total Studies
10
Human Studies
4

The clinical evidence for Pentapeptide-18 is consistent but limited in scope and rigor. The manufacturer's 2005 in-vivo studies (Lipotec) across three arms (14-15 volunteers each, 28 days) demonstrated 11.64% wrinkle reduction for Leuphasyl alone and 24.62% for the combination with Argireline. Dragomirescu et al. (2014) independently confirmed efficacy at 2% concentration in 20 volunteers over 2 months (34.7% frontal, 28.4% periorbital wrinkle reduction) and established a dose-response threshold. Two 2024 studies by Pawlowska et al. showed improved delivery via nanoparticle formulations. Park et al. (2020) added anti-melanogenic evidence using D-tyrosine derivatives. All studies report excellent safety with no adverse effects. However, there are no large RCTs, no long-term safety data beyond 2 months, and most core efficacy claims rest on manufacturer-sponsored data. The evidence is sufficient for cosmetic claims but far below pharmaceutical standards.

Researched for(6)

Rated by confidence in the evidence

  • Reduction of expression wrinkles (forehead lines, crow's feet, frown lines)

    Speculative

    Published human studies exist, including a 20-person uncontrolled study in 2014; rigorous evidence isolating the peptide's effect remains limited.

    PMID 41722287 (Comput Biol Chem 2026, 'Pentapeptide-18 as an anti-aging candidate' - spectroscopic/computational study; narrative restatement of supplier claims); no identified ClinicalTrials.gov registrations for pentapeptide-18

  • Synergistic wrinkle reduction when combined with Argireline (Acetyl Hexapeptide-8)

    Speculative

    Marketing rationale only; no published study has tested the combination in humans or cells.

    No identified PubMed-indexed combination study for pentapeptide-18 plus acetyl hexapeptide-8; no identified ClinicalTrials.gov registrations

  • Non-invasive Botox-like muscle relaxation without loss of facial expressivity

    Speculative

    Mechanism-based only; no human EMG studies or comparisons with botulinum toxin exist.

    PMID 41722287 (Comput Biol Chem 2026; spectroscopic/computational characterization only)

  • Enhanced delivery and stability in nanoparticle formulations

    Low

    The 2024 IJMS study also evaluated combination eye creams in humans for eight weeks; those results do not isolate Pentapeptide-18's contribution.

    PMID 39337562 (Int J Mol Sci 2024, 'Solid Lipid Nanoparticles Incorporated with Retinol and Pentapeptide-18'); PMID 39459512 (Life 2024, 'Retinol and Oligopeptide-Loaded Lipid Nanocarriers')

  • Anti-melanogenic (skin-brightening) potential when modified with D-tyrosine

    Speculative

    Based on one unreplicated 2020 lab study of a modified conjugate, not standard peptide.

    PMID 31937863 / PMC6959337 (Sci Rep 2020;10:262)

  • Computational evidence for interactions with aging-related signaling pathways

    Speculative

    Docking simulations predict binding to aging pathways; not yet shown in cells or people.

    PMID 41722287 (Comput Biol Chem 2026); PMID 42116636 (Chem Biodivers 2026, 'Integrative In Silico and In Vitro Evaluation of Vialox and Leuphasyl')

Benefits(6)

  • Reduction of expression wrinkles (forehead lines, crow's feet, frown lines)

    Lipotec 2005 (manufacturer in-vivo study) — 14 volunteers, 28 days, 5% Leuphasyl solution (0.05% active) applied twice daily around eyes: 11.64% mean wrinkle depth reduction, max -23.55%. Dragomirescu et al. 2014 (Cosmetics, DOI 10.3390/cosmetics1020075) — 20 volunteers, 2 months daily application, 2% concentration: 34.7% frontal wrinkle reduction, 28.4% periorbital reduction. Lower concentrations (0.5%, 1%) showed no significant effect.

  • Synergistic wrinkle reduction when combined with Argireline (Acetyl Hexapeptide-8)

    Lipotec 2005 (manufacturer in-vivo study) — 15 volunteers, 28 days, 5% Leuphasyl + 5% Argireline solution: 24.62% mean wrinkle depth reduction (max -46.53%), compared to 11.64% for Leuphasyl alone and 16.26% for Argireline alone. Synergy attributed to complementary mechanisms: Leuphasyl inhibits at enkephalin receptor level, Argireline inhibits SNARE complex assembly. Gorouhi et al. 2009 (Int J Cosmet Sci) review confirmed synergistic potential.

  • Non-invasive Botox-like muscle relaxation without loss of facial expressivity

    Lipotec 2005 and Dragomirescu et al. 2014 — Unlike botulinum toxin injections, which paralyze facial muscles and can impair expression, Pentapeptide-18 modulates rather than abolishes acetylcholine release, preserving natural facial movement while reducing wrinkle depth. Safety testing confirmed no cytotoxicity, genotoxicity, or skin irritation.

  • Enhanced delivery and stability in nanoparticle formulations

    Pawlowska et al. 2024 (Int J Mol Sci, PMID 39337562; Life, PMID 39459512) — Solid lipid nanoparticles (SLNs) incorporating Pentapeptide-18 with retinol demonstrated stable particle size (134.7 nm), favorable zeta potential (42.7 mV), and improved cosmetic efficacy in reducing wrinkles and sebum secretion over 8 weeks in 20 female volunteers (aged 30-65), while reducing the irritating effects typically associated with retinoid therapy.

  • Anti-melanogenic (skin-brightening) potential when modified with D-tyrosine

    Park et al. 2020 (Scientific Reports, PMID 31937863) — Addition of terminal D-tyrosine to Pentapeptide-18 inhibited melanogenesis induced by alpha-MSH and UV irradiation in human MNT-1 melanoma cells, primary melanocytes, and 3D human skin models. Reduced melanin content and tyrosinase activity more effectively than D-tyrosine alone. Suggests dual-function anti-wrinkle and skin-brightening cosmeceutical applications.

  • Computational evidence for interactions with aging-related signaling pathways

    Akhan et al. 2026 (Computational Biology and Chemistry, PMID 41722287) — Molecular dynamics simulations and spectroscopic analysis showed Pentapeptide-18 interacts with molecular targets in TGF-beta, TNF-alpha, MAPK, PI3K/AKT, and NF-kB pathways, supporting its candidacy as a non-invasive anti-aging agent. Computational study only; no in-vivo validation yet.

Key studies(7)

  1. Leuphasyl: A New Pentapeptide for Expression Wrinkles (PD080)

    Manufacturer in-vivo study (open-label)14-15 volunteers per arm (3 arms: Leuphasyl alone, Argireline alone, combination)28 days, twice daily application around eyes

    Lipotec S.A.

    Manufacturer Technical Data Sheet

    2005

    Pivotal efficacy data for Pentapeptide-18. Leuphasyl 5% solution (0.05% active): 11.64% mean wrinkle reduction (max -23.55%) in 14 volunteers aged 39-64. Argireline 5% solution: 16.26% mean reduction (max -31.80%) in 14 volunteers aged 39-63. Combination: 24.62% mean reduction (max -46.53%) in 15 volunteers aged 39-63. No cytotoxicity, genotoxicity, or skin irritation observed. Recommended usage: 3-10% of solution in final formulation.

  2. The Efficiency and Safety of Leuphasyl -- A Botox-Like Peptide

    Open-label clinical study20 volunteers2 months, daily application

    Dragomirescu AO, Andoni M, Ionescu D, Andrei F

    Cosmetics

    2014

    First independent peer-reviewed study on Pentapeptide-18. Tested three concentrations (0.5%, 1%, 2%) using Pro-Derm Analyzer imaging. Only 2% concentration achieved significant wrinkle reduction: 34.7% between eyebrows, 28.4% around eye contour. Established 2% as minimum effective threshold. Lower concentrations showed no significant improvement. Confirmed excellent safety profile with no adverse effects.

  3. D-tyrosine adds an anti-melanogenic effect to cosmetic peptides

    In-vitro and 3D skin model studyCell lines (MNT-1 melanoma, primary melanocytes, 3D human skin model)In-vitro assays

    Park J, Jung H, Jang B, Song HK, Han IO, Oh ES

    Scientific Reports

    2020

    Terminal D-tyrosine added to Pentapeptide-18 endowed the peptide with anti-melanogenic activity: inhibited melanogenesis induced by alpha-MSH and UV irradiation, reduced melanin content and tyrosinase activity in human melanocytes and 3D skin models more effectively than D-tyrosine alone. Demonstrated feasibility of dual-function anti-wrinkle + skin-brightening cosmeceutical peptides.

  4. Solid Lipid Nanoparticles Incorporated with Retinol and Pentapeptide-18 -- Optimization, Characterization, and Cosmetic Application

    Formulation optimization and in-vivo cosmetic study20 female volunteers (aged 30-65) for in-vivo portion8 weeks application, 4 weeks stability testing

    Pawlowska M, Marzec M, Jankowiak W, Nowak I

    International Journal of Molecular Sciences

    2024

    Developed stable solid lipid nanoparticles (SLNs) co-loading retinol and Pentapeptide-18 (mean particle size 134.7 nm, zeta potential 42.7 mV). Demonstrated improved stability at 25 degrees C storage. In-vivo testing showed significant improvements in wrinkle reduction and skin elasticity, with reduced irritation compared to conventional retinol formulations.

  5. Retinol and Oligopeptide-Loaded Lipid Nanocarriers as Effective Raw Material in Anti-Acne and Anti-Aging Therapies

    In-vivo clinical study with formulation characterizationHuman volunteers (anti-acne and anti-aging evaluation)Multi-week stability and efficacy evaluation

    Pawlowska M, Marzec M, Jankowiak W, Nowak I

    Life (Basel)

    2024

    Lipid nanocarriers containing Pentapeptide-18 and retinol showed significant reduction in sebum secretion, decreased facial wrinkles, and reduced the irritating effects of retinol typically seen in standard retinoid therapy. Confirmed nanoparticle delivery as a viable strategy for improving peptide bioavailability in cosmetic formulations.

  6. Pentapeptide-18 as an anti-aging candidate: Spectroscopic characterization and molecular interaction analysis

    Computational study (DFT, molecular dynamics, spectroscopy)In-silico / spectroscopic analysisN/A (computational)

    Akhan D, Bicak B, Akalin E, Kecel Gunduz S

    Computational Biology and Chemistry

    2026

    Combined density functional theory, molecular orbital analysis, molecular dynamics simulations, and experimental spectroscopy (FTIR, ATR-FTIR, Raman) to characterize Pentapeptide-18. Examined interactions with aging-related molecular targets including TGF-beta, TNF-alpha, MAPK, PI3K/AKT, and NF-kB pathways. Results support Pentapeptide-18 as a viable candidate for non-invasive anti-aging skincare applications.

  7. Pintea A, Manea A, Pintea C, Vlad RA, Birsan M, Antonoaea P, Redai EM, Ciurba A

    Biomolecules

    2025

    Comprehensive review classifying Pentapeptide-18 as a neurotransmitter inhibitor peptide within the cosmeceutical peptide landscape. Discusses delivery challenges (poor membrane permeability), physical enhancement techniques (microneedles, electroporation, ultrasound), and nano-formulation systems to improve peptide bioavailability.

Regulation & availability

Why researchers look at it

An independent clinical study (20 volunteers, 2 months) found 35% wrinkle reduction on the forehead and 28% around the eyes, while combining it with Argireline pushed reduction to nearly 47% in some subjects. No adverse effects reported in any published study. As a topical neuropeptide that softens rather than paralyzes facial muscles, it offers visible wrinkle reduction without the cost or frozen look of injectables.

Estimated cost
$15-50/mo in OTC serums
FDA status
Pentapeptide-18 is not FDA-approved as a drug. It is used in topical cosmetics, which generally do not require premarket approval except for color additives; a product that claims to treat a condition or change how the body works is regulated as a drug. UNII PO4D55T1IG identifies the ingredient and does not establish approval or safety. It is also catalogued in PubChem (CID 10099522), and the EWG Skin Deep database lists it as not currently on restricted or unacceptable ingredient lists. Manufacturers must substantiate finished-product safety and meet applicable cosmetic requirements. No approved drug product was identified; confidential NDA or IND submissions cannot be excluded from public records.
WADA status
Not expressly named in the 2026 List. Absence from S2 does not exclude S0 coverage of unapproved pharmacological substances. Ingredient-specific clearance was not established; obtain an authoritative anti-doping determination.
Prescribability
No — Pentapeptide-18 (Leuphasyl) is not a prescription drug. It is classified as a cosmetic ingredient, not a pharmaceutical agent, and is used exclusively in topical skincare formulations. It is regulated under cosmetics law (not drug law) in most jurisdictions and is not subject to pharmaceutical prescribing, dispensing, or compounding requirements.
Availability
Pentapeptide-18 (Leuphasyl) is widely available as a cosmetic ingredient and in finished skincare products without a prescription. Finished cosmetic products include anti-aging serums, eye creams, and wrinkle-targeting treatments from numerous cosmetic brands; it is often found alongside Argireline (Acetyl Hexapeptide-8), including in the combination product Argirelox. The raw cosmetic ingredient is supplied as a water-soluble aqueous solution or lyophilized powder. For DIY cosmetic formulation, the recommended incorporation rate is 3-10% of the Leuphasyl solution in final formulations. It is a cosmetic ingredient, not a controlled substance or pharmaceutical drug.

International status

  • EU

    Available OTC in cosmetics (INCI listed)

  • US

    Available OTC in cosmetic products (not a drug)

  • Worldwide

    Regulated as cosmetic ingredient, not pharmaceutical

Regulatory timeline(11)

  1. 1975
    Hughes et al. discover leu-enkephalin (Tyr-Gly-Gly-Phe-Leu), the endogenous opioid pentapeptide that Pentapeptide-18 is designed to mimic.
  2. 1980s
    Dalargin (Tyr-D-Ala-Gly-Phe-Leu-Arg), the hexapeptide parent compound of Pentapeptide-18, enters clinical use in Eastern Europe for gastrointestinal conditions.
  3. 2005-06
    Lipotec S.A. (Barcelona, Spain) publishes first technical documentation for Leuphasyl (PD080), a new pentapeptide for expression wrinkles. Includes three in-vivo clinical studies demonstrating efficacy and safety.
  4. 2005
    Lipotec introduces Argirelox, the combination product of Leuphasyl (Pentapeptide-18) + Argireline (Acetyl Hexapeptide-8) for synergistic wrinkle reduction.
  5. 2009
    Gorouhi et al. publish comprehensive review of topical peptides for aged skin in International Journal of Cosmetic Science, including Leuphasyl efficacy data and synergy with Argireline.
  6. 2014-04
    Dragomirescu et al. publish first independent peer-reviewed clinical study on Leuphasyl in Cosmetics (MDPI), establishing 2% as minimum effective concentration in 20 volunteers.
  7. 2020-01
    Park et al. publish in Scientific Reports demonstrating that D-tyrosine modification of Pentapeptide-18 adds anti-melanogenic properties, creating dual-function cosmeceutical potential.
  8. 2012
    Lipotec S.A. is acquired by Lubrizol Corporation (Berkshire Hathaway subsidiary); Leuphasyl product continues under Lubrizol Personal Care portfolio.
  9. 2024-09
    Pawlowska et al. publish two studies on solid lipid nanoparticle delivery systems for Pentapeptide-18 + retinol in International Journal of Molecular Sciences and Life.
  10. 2025-01
    Pintea et al. publish comprehensive review in Biomolecules classifying Pentapeptide-18 as a neurotransmitter inhibitor peptide in the emerging cosmeceutical peptide landscape.
  11. 2026-02
    Akhan et al. publish computational study in Computational Biology and Chemistry examining Pentapeptide-18 interactions with aging-related molecular pathways (TGF-beta, MAPK, NF-kB).

Sources & FAQs

Research sources(13)

Frequently asked questions(6)

How does Pentapeptide-18 compare to Botox for wrinkle reduction?

Pentapeptide-18 works through a similar principle — reducing neuromuscular signaling that causes facial muscle contractions — but is far less potent than botulinum toxin. Botox achieves near-complete paralysis of targeted muscles via injection, producing dramatic wrinkle reduction (typically 80-90%). Pentapeptide-18, applied topically, achieves more modest results (11-35% wrinkle reduction depending on concentration and study). The key advantages of Pentapeptide-18 are: no needles required, no risk of muscle paralysis, preservation of natural facial expression, no medical supervision needed, and continuous availability over the counter. It is best suited for mild to moderate expression lines or as a maintenance treatment between Botox sessions.

What concentration of Pentapeptide-18 is needed for results?

The independent clinical study by Dragomirescu et al. (2014) established that 2% is the minimum effective concentration, with lower concentrations (0.5% and 1%) failing to produce significant wrinkle reduction. The manufacturer (Lipotec) recommends incorporating 3-10% of the Leuphasyl solution into final formulations, which corresponds to approximately 0.03-0.1% active peptide in the finished product. The manufacturer's clinical studies used 5% solution (0.05% active peptide). For best results, look for products listing Pentapeptide-18 prominently in the ingredient list and apply to all facial muscle areas involved in expression, not just visible wrinkles.

Is Pentapeptide-18 safe for all skin types?

All available studies report excellent tolerance with no skin irritation, allergic reactions, or adverse effects. Manufacturer testing showed no cytotoxicity, genotoxicity, or sensitization. It is generally considered safe for all skin types. However, individuals with extremely sensitive skin or known allergies to peptide ingredients should perform a patch test before widespread use. Because it is a topical cosmetic ingredient with minimal systemic absorption, it is not expected to interact with medications or affect systemic physiology.

Does Pentapeptide-18 work better combined with Argireline?

In the manufacturer's 2005 in-vivo study, the combination did better than either peptide alone: Leuphasyl alone achieved 11.64% wrinkle reduction, Argireline alone 16.26%, and the combination 24.62%, exceeding either individual result. These percentages alone do not establish synergy. The two peptides act at different stages of the neuromuscular signaling cascade: Leuphasyl reduces neuronal excitability at the receptor level (upstream), while Argireline blocks SNARE complex assembly (downstream). The combination is commercially available as Argirelox from Lipotec/Lubrizol.

Is Pentapeptide-18 the same as leu-enkephalin?

No, but they are closely related. Leu-enkephalin (Tyr-Gly-Gly-Phe-Leu) is the natural endogenous opioid pentapeptide found in the body. Pentapeptide-18 (Tyr-D-Ala-Gly-Phe-Leu) is a synthetic analog in which the second glycine is replaced with D-alanine. The D-amino acid substitution is a common pharmaceutical strategy to improve metabolic stability against peptidase degradation while retaining receptor binding affinity. Pentapeptide-18 is also closely related to Dalargin (Tyr-D-Ala-Gly-Phe-Leu-Arg), a hexapeptide used therapeutically for gastrointestinal conditions, differing only by the absence of the C-terminal arginine.

Can Pentapeptide-18 be absorbed through the skin?

Pentapeptide-18 can penetrate skin to a limited extent, which is a notable advantage over many larger peptides. However, poor membrane permeability remains a challenge for topical peptides generally (Pintea et al. 2025 review). Modern formulation strategies such as solid lipid nanoparticles (Pawlowska et al. 2024), liposomes, microneedle patches, and electroporation can significantly enhance skin penetration and peptide bioavailability. The clinical studies showing efficacy at 2%+ concentrations confirm sufficient transdermal delivery for biological activity when properly formulated.